Clinical Update of Opioid Agonist and Partial Agonist Medications for the Maintenance Treatment of Opioid Addiction

Kreek, 1975, Pharmacologic modalities of therapy: Methadone maintenance and the use of narcotic antagonists Cooper, 1983, Health consequences associated with use of methadone Hartman, 1983, Narcotic poisoning Kreek, 1991, Using methadone effectively: Achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs, 245 Kreek, 1992, Rationale for maintenance pharmacotherapy of opiate dependence, 205 M. J. Kreek, 1992, Epilogue: Medical Maintenance Treatment for Heroin Addiction, from a Retrospective and Prospective Viewpoint, 255, 272, State Methadone Maintenance Treatment Guidelines Office for Treatment Improvement, Division for State Assistance Wodak, 1994, Managing illicit drug use, Drugs, 3, 446, 10.2165/00003495-199447030-00005 Ling, 1994, Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine, J. Psychoactive Drugs, 26, 119, 10.1080/02791072.1994.10472259 Rettig, 1994 Vocci, 1995, Overview: Medications development for the treatment of drug abuse, NIDA Res. Monogr., 149, 4 Kreek, 1996, Long-term pharmacotherapy for opiate (primarily heroin) addiction: Opiate Agonists, 487 Kreek, 1996, Long-term pharmacotherapy for opiate (primarily heroin) addiction: Opiate antagonists and partial agonists, 563 Kreek, 1996, Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity and in specific addictive diseases, J. Neurochem. Res., 21, 1469, 10.1007/BF02532387 Dole, 1965, A medical treatment for diacetylmorphine (heroin) addiction, J. Am. Med. Assoc., 193, 646, 10.1001/jama.1965.03090080008002 Dole, 1966, Narcotic blockade, Arch. Intern. Med., 118, 304, 10.1001/archinte.1966.00290160004002 M. J. Kreek, 1972, Medical safety, side effects and toxicity of methadone, Proceedings of the Fourth National Conference on Methadone Treatment, 171, 174, NAPAN-NIMH Kreek, 1972, Long-term methadone maintenance therapy: Effects on liver function, Ann. Intern. Med., 77, 598, 10.7326/0003-4819-77-4-598 Inturrisi, 1972, The levels of methadone in the plasma in methadone maintenance, Clin. Pharmacol. Ther., 13, 633, 10.1002/cpt1972135part1633 Kreek, 1973, Plasma and urine levels of methadone, NY State J. Med., 73, 2773 Kreek, 1973, Physiological implications of methadone treatment Kreek, 1973, Medical safety and side effects of methadone in tolerant individuals, J. Am. Med. Assoc., 223, 665, 10.1001/jama.1973.03220060039009 Dole, 1973, Methadone plasma levels: Sustained by a reservoir of drug in tissue, Proc. Natl. Acad. Sci. USA, 70, 10, 10.1073/pnas.70.1.10 Cushman, 1974, Methadone-maintained patients. Effects of methadone on plasma testosterone, FSH, LH and prolactin, NY State J. Med., 74, 1970 Cushman, 1974, Some endocrinologic observations in narcotic addicts, 161 Kreek, 1976, Rifampin-induced methadone withdrawal, N. Engl. J. Med., 294, 1104, 10.1056/NEJM197605132942008 Kreek, 1978, Medical complications in methadone patients, Ann. NY Acad. Sci., 311, 110, 10.1111/j.1749-6632.1978.tb16769.x Kreek, 1979, Stereoselective disposition of methadone in man, Life Sci., 24, 925, 10.1016/0024-3205(79)90343-6 Kreek, 1979, Methadone disposition during the perinatal period in humans, Pharmacol. Biochem. Behav., II, 1 Kreek, 1981, Metabolic interactions between opiates and alcohol, Ann. NY Acad. Sci., 362, 36, 10.1111/j.1749-6632.1981.tb12789.x Kreek, 1981, Effects of chronic exogenous opioid administration on levels of one endogenous opioid (beta-endorphin) in man, 364 Nakamura, 1982, Quantitation of methadone enantiomers in humans using stable isotope-labeled232528, J. Pharmacol. Sci., 71, 39, 10.1002/jps.2600710110 Kreek, 1982, Chronic use of opioids and antipsychotic drugs: Side effects, effects on endogenous opioids and toxicity, Ann. NY Acad. Sci., 398, 151, 10.1111/j.1749-6632.1982.tb39489.x Kreek, 1983, Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans, Life Sci., 33, 409, 10.1016/0024-3205(83)90529-5 Kreek, 1984, ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans, Neuropeptides, 5, 277, 10.1016/0143-4179(84)90081-7 Pond, 1985, Altered methadone pharmacokinetics in methadone-maintained pregnant women, J. Pharmacol. Exp. Ther., 233, 1 Hanbury, 1986, Cocaine use in persons on methadone maintenance, Adv. Alcohol Subst. Abuse, 6, 97, 10.1300/J251v06n02_07 Novick, 1988, Methadone maintenance patients in general medical practice, J. Am. Med. Assoc., 259, 3299, 10.1001/jama.1988.03720220045024 Novick, 1989, Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients, J. Pharmacol. Exp. Ther., 250, 606 Kennedy, 1990, Metyrapone-induced withdrawal symptoms, Brit. J. Addict., 85, 1133, 10.1111/j.1360-0443.1990.tb03438.x Ball, 1991 Culpepper-Morgan, 1992, Treatment of opioid induced constipation with oral naloxone: A pilot study, Clin. Pharmacol. Ther., 23, 90, 10.1038/clpt.1992.106 Unterwald, 1992, Chronic cocaine alters brain mu opioid receptors, Brain Res., 584, 314, 10.1016/0006-8993(92)90912-S Novick, 1993, The medical status of methadone maintained patients in treatment for 11–18 years, Drug and Alcohol Dep., 33, 235, 10.1016/0376-8716(93)90110-C McLellan, 1993, The effects of psychosocial services in substance abuse treatment, J. Am. Med. Assoc., 269, 1953, 10.1001/jama.1993.03500150065028 Unterwald, 1994, Repeated cocaine administration upregulates kappa and mu, but not delta opioid receptors, NeuroReport, 5, 1613, 10.1097/00001756-199408150-00018 Borg, 1995, Cocaine abuse is decreased with effective methadone maintenance treatment at an urban Department of Veterans Affairs (DVA) Program, 17 Zhou, 1996, Steady-state methadone in rats does not change mRNA levels of cortisotropin-releasing factor, its pituitary receptor or poopiomelanocortin, Eur. J. Pharmacol., 315, 31, 10.1016/S0014-2999(96)00672-3 Zhou, 1996, Corticotropin-releasing factor and CRF-R1 mRNAs in rat brain and pituitary during “binge” pattern cocaine administration and chronic withdrawal, J. Pharmacol. Exp. Ther., 279, 351 Kreek, 1996, Opiates, opioids and addiction, Mol. Psych., 1, 232 Zubieta, 1996, Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving, Nature Med., 2, 1225, 10.1038/nm1196-1225 Culpepper-Morgan, 1997, HPA axis hypersensitivity to naloxone in opioid dependence: A case of naloxone induced withdrawal, Metabolism, 46, 130, 10.1016/S0026-0495(97)90289-4 Des Jarlais, 1984, Antibodies to a retrovirus etiologically associated with Acquired Immunodeficiency Syndrome (AIDS) in populations with increased incidences of the syndrome, MMWR, 33, 377 Novick, 1986, Antibody to LAV, the putative agent of AIDS, in parenteral drug abusers and methadone-maintained patients: Abstract of clinical research findings: Therapeutic, historical, and ethical aspects, 318 Novick, 1986, Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection, United Nations Bulletin on Narcotics, 38,, 15 Novick, 1989, Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City, J. Med. Virol., 29, 181, 10.1002/jmv.1890290307 Chaisson, 1989, Cocaine use and HIV infection in intravenous drug users in San Francisco, J. Am. Med. Assoc., 261, 561, 10.1001/jama.1989.03420040099027 Des Jarlais, 1989, HIV-1 infection among intravenous drug users in Manhattan, New York City 1977 to 1987, J. Am. Med. Assoc., 261, 1008, 10.1001/jama.1989.03420070058030 Kreek, 1990, Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS, J. Infect. Dis., 162, 538, 10.1093/infdis/162.2.538 Schwartz, 1992, Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection, J. Acquired Immune Defic. Syd., 5, 619 Metzger, 1993, Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: An 18-month prospective follow-up, J. Acquired Immune Defic. Syndr., 6, 1049 Borg, 1995, Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-positive and AIDS patients, Curr. Opin. Psychiatr., 8, 199, 10.1097/00001504-199505000-00014 Jaffe, 1970, Comparison of acetylmethadol and methadone in the treatment of long-term heroin users, J. Am. Med. Assoc., 211, 1834, 10.1001/jama.1970.03170110040008 Jaffe, 1971, Methadone andl, J. Am. Med. Assoc., 216, 1303, 10.1001/jama.1971.03180340023005 Jaffe, 1972, Methadyl acetate v. methadone: A double-blind study in heroin users, J. Am. Med. Assoc., 222, 437, 10.1001/jama.1972.03210040013004 Zaks, 1972, Levomethadyl in maintenance treatment of opiate dependence, J. Am. Med. Assoc., 220, 811, 10.1001/jama.1972.03200060039005 Ling, 1975, Current status of the evaluation of LAAM as a maintenance drug for heroin addicts, Am. J. Drug Alcohol Abstr., 2, 307, 10.3109/00952997509005656 Blaine, 1976, RX 3× a week LAAM: Alternative to methadone, DHEW-NIDA Research Monograph, Series 8 Ling, 1976, Methadyl acetate and methadone as maintenance treatments for heroin addicts: A Veterans Administration cooperative study, Arch. Gen. Psych., 33, 709, 10.1001/archpsyc.1976.01770060043007 Mendelson, 1976, Effects of acetylmethadol on plasma testosterone, Clin. Pharmacol. Ther., 19, 371, 10.1002/cpt1976193371 Gevert, 1977, Failure of methadone and levomethadyl acetate (Levo-alpha-acetylmethadol) maintenance to affect memory, Arch. Gen. Psych., 34, 849, 10.1001/archpsyc.1977.01770190111011 Blaine, 1978, Clinical use of LAAM, Ann. NY Acad. Sci., 311, 214, 10.1111/j.1749-6632.1978.tb16778.x Crowley, 1979, Every-other-day acetylmethadol disturbs circadian cycles of human motility, Psychopharmacology (Berlin), 62, 151, 10.1007/BF00427129 Judson, 1979, Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts I. Dosage schedule for induction and stabilization, Drug Alcohol Dep., 4, 461, 10.1016/0376-8716(79)90024-3 Judson, 1982, Symptom complaints of patients maintained on methadone, LAAM (methadyl acetate), and naltrexone at different times in their addiction careers, Drug Alcohol Dep., 10, 269, 10.1016/0376-8716(82)90021-7 Mendelson, 1984, Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal, Clin. Pharmacol. Ther., 15, 545, 10.1038/clpt.1984.75 1993 Abramowic, 1994, LAAM: A long-acting methadone for treatment of heroin addiction, Med. Lett., 36, 52 Prendergast, 1995, Levo-alpha-acetylmethadol (LAAM): Clinical, research, and policy issues of a new pharmacotherapy for opioid addiction, J. Psychoactive Drugs, 27, 239, 10.1080/02791072.1995.10472469 Lewis, 1970, Novel analgetics and molecular rearrangements in morphine–thebaine group XVIII 3-deoxy-6,14-endo-etheno-6,7,8,14-tetrahydrooripavines, J. Med. Chem., 13, 525, 10.1021/jm00297a041 Cowan, 1977, Agonist and antagonist properties of buprenorphine, a new antinociceptive agent, Br. J. Pharmacol., 60, 537, 10.1111/j.1476-5381.1977.tb07532.x Jasinski, 1978, Human pharmacology and abuse potential of the analgesic buprenorphine, Arch. Gen. Psych., 35, 501, 10.1001/archpsyc.1978.01770280111012 Heel, 1979, Buprenorphine: A review of its pharmacological properties and therapeutic efficacy, Drugs, 17, 81, 10.2165/00003495-197917020-00001 McQuay, 1980, Clinical effects of buprenorphine during and after operation, Br. J. Anaesth., 52, 1013, 10.1093/bja/52.10.1013 Mello, 1980, Buprenorphine suppresses heroin use by heroin addicts, Science, 207, 657, 10.1126/science.7352279 Mello, 1982, Buprenorphine effects on human heroin self-administration: An operate analysis, J. Pharmacol. Exp. Ther., 223, 30 Mendelson, 1982, Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts, J. Pharmacol. Exp. Ther., 220, 252 Bullingham, 1983, Clinical pharmacokinetics of narcotic agonist-antagonist drugs, Clin. Pharmacol., 8, 332, 10.2165/00003088-198308040-00004 Cone, 1984, The metabolism and excretion of buprenorphine in humans, Drug Met. Disp., 12, 577 Reisinger, 1985, Buprenorphine as new treatment for heroin dependence, Drug Alcohol Dep., 16, 257, 10.1016/0376-8716(85)90050-X Lehmann, 1988, Influence of naloxone on the postoperative analgesic and respiratory effects of buprenorphine, Eur. J. Clin. Pharmacol., 34, 343, 10.1007/BF00542434 Bickel, 1988, Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans, J. Pharmacol. Exp. Ther., 247, 47 Weinberg, 1988, Sublingual absorption of selected opioid analgesics, Clin. Pharmacol. Ther., 44, 335, 10.1038/clpt.1988.159 Johnson, 1989, Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction, Clin. Pharmacol. Ther., 46, 335, 10.1038/clpt.1989.147 Kosten, 1989, Treatment of cocaine abuse with buprenorphine, Biol. Psych., 26, 170 Mendelson, 1989, Naloxone suppresses buprenorphine stimulation of plasma prolactin, J. Clin. Psychopharmacol., 9, 105, 10.1097/00004714-198904000-00006 Fudala, 1990, Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal, Clin. Pharmacol. Ther., 47, 525, 10.1038/clpt.1990.67 Kosten, 1992, Beta-endorphin levels during heroin, methadone, buprenorphine and naloxone challenges: Preliminary findings, Biol. Psych., 32, 523, 10.1016/0006-3223(92)90220-T Kosten, 1992, Buprenorphine for cocaine and opiate dependence, Psychopharmacol. Bull., 28, 15 Blaine, 1992, Introduction (to Buprenorphine: An alternative treatment for opioid dependence), NIDA Res. Monogr., 121, 1 Johnson, 1992, A controlled trial of buprenorphine treatment for opioid dependence, J. Am. Med. Assoc., 267, 2750, 10.1001/jama.1992.03480200058024 Kosten, 1993, Buprenorphine versus methadone maintenance for opioid dependence, J. Nerv. Ment. Dis., 181, 358, 10.1097/00005053-199306000-00004 Mendelson, 1996, Buprenorphine and naloxone interactions in opiate-dependent volunteers, Clin. Pharmacol. Ther., 60, 105, 10.1016/S0009-9236(96)90173-3 Ling, 1996, A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence, Arch. Gen. Psychiatr., 53, 401, 10.1001/archpsyc.1996.01830050035005 Goldstein, 1979, Dynorphin(1–13), an extraordinarily potent opioid peptide, Proc. Natl. Acad. Sci. USA, 145, 267 Chavkin, 1982, Dynorphin is a specific endogenous ligand of the kappa opioid receptor, Science, 215, 413, 10.1126/science.6120570 Aceto, 1982, Dynorphin(1–13) effects in nontolerant and morphine-dependent rhesus monkeys, Eur. J. Pharmacol., 83, 139, 10.1016/0014-2999(82)90299-0 Wen, 1982, Suppression of withdrawal symptoms by dynorphin in heroin addicts, Eur. J. Pharmacol., 82, 183, 10.1016/0014-2999(82)90509-X Young, 1987, The degradation of dynorphin A in brain tissuein vivoin vitro, Peptides, 8, 701, 10.1016/0196-9781(87)90046-5 Green, 1988, Dynorphin A(1–13) attenuates withdrawal in morphine-dependent rats: Effect of route of administration, Eur. J. Pharmacol., 145, 267, 10.1016/0014-2999(88)90429-3 Takemori, 1992, Suppression by dynorphin A(1–13) of the expression of opiate withdrawal and tolerance in mice, Eur. J. Pharmacol., 221, 223, 10.1016/0014-2999(92)90705-9 Chou, 1993, Study of opioid peptides by laser desorption mass spectrometry, 380 Takemori, 1993, Suppression by dynorphin A and (Des-Tyr) dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice, J. Pharmacol. Exp. Ther., 266, 121 Kreek, 1994, Dynorphin A1–13, 108 Chou, 1994, Matrix-assisted laser desorption mass spectrometry of biotransformation products of dynorphin Ain vitro, J. Am. Soc. Mass Spectrom., 5, 10, 10.1016/1044-0305(94)85078-X Uneklabh, 1995, Clinical effect of dynorphin on heroin addicts, J. Med. Assoc. Thai., 78, 509 Hooke, 1995, Dynorphin A modulates acute and chronic opioid effects, J. Pharmacol. Exp. Ther., 273, 292 Claye, 1996, Both Dynorphin A1–1712–17, J. Pharmacol. Exp. Ther., 277, 359 Chou, 1996, Differential biotransformation of dynorphin A1–171–13ex vivo, Peptides, 17, 983, 10.1016/0196-9781(96)00154-4 Yu, 1996, In vitro1–17, J. Pharmacol. Exp. Ther., 279, 507 J. M. Ingham, N. I. Cherny, P. J. Tiseo, A. Caraceni, J. Lapin, C. Inturrisi, R. Goldblum, J. H. Johnson, M. J. Kreek, K. M. Foley, R. K. Portenoy, 1996, A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Dynorphin A (1–13) in Opioid-Treated Patients with Chronic Pain Yu, 1996, Nociceptinin vitro, Peptides, 17, 873, 10.1016/0196-9781(96)00079-4 Yu, 1997, Dynorphin A(1–8) analog, E-2078, is stable in human and rhesus monkey blood, J. Pharmacol. Exp. Ther., 280, 1147 Claye, 1997, Local perfusion of dynorphin A1–17 Specker, 1997, Effects of dynorphin on opiate addiction in humans Borg, 1998, Dynorphin A(1–13) elevates serum prolactin levels by an opioid receptor mechanism:controlled studies of normal volunteers